Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Bruno Halpern & Alfredo Halpern. (2015) Safety assessment of FDA-approved (orlistat and lorcaserin) anti-obesity medications. Expert Opinion on Drug Safety 14:2, pages 305-315.
Read now
Read now
Natalia Catoira, Mara Nagel, Guillermo Di Girolamo & Claudio D Gonzalez. (2010) Pharmacological treatment of obesity in children and adolescents: current status and perspectives. Expert Opinion on Pharmacotherapy 11:18, pages 2973-2983.
Read now
Read now
Articles from other publishers (18)
Walter Milano, Valeria De Biasio, Walter Di Munzio, Giuseppina Foggia & Anna Capasso. (2020) Obesity: The New Global Epidemic Pharmacological Treatment, Opportunities and Limits for Personalized Therapy. Endocrine, Metabolic & Immune Disorders - Drug Targets 20:8, pages 1232-1243.
Crossref
Crossref
Ulf Holmbäck, Anders Forslund, Stefan Grudén, Göran Alderborn, Arvid Söderhäll, Per M. Hellström & Hans Lennernäs. (2020) Effects of a novel combination of orlistat and acarbose on tolerability, appetite, and glucose metabolism in persons with obesity. Obesity Science & Practice 6:3, pages 313-323.
Crossref
Crossref
Steven Johnson & Susan M. Schwartz. (2018) Pharmacologic and Pharmacodynamic Equivalence of 2 Formulations of Orlistat. Clinical Pharmacology in Drug Development 7:7, pages 773-780.
Crossref
Crossref
Xiguang Qi. (2018) Review of the Clinical Effect of Orlistat. IOP Conference Series: Materials Science and Engineering 301, pages 012063.
Crossref
Crossref
Vidya Narayanaswami & Linda P. Dwoskin. (2017) Obesity: Current and potential pharmacotherapeutics and targets. Pharmacology & Therapeutics 170, pages 116-147.
Crossref
Crossref
Cristina Cruz-Hernandez, Frédéric Destaillats, Sagar K. Thakkar, Laurence Goulet, Emma Wynn, Dominik Grathwohl, Claudia Roessle, Sara de Giorgi, Luc Tappy, Francesca Giuffrida & Vittorio Giusti. (2016) Monoacylglycerol-enriched oil increases EPA/DHA delivery to circulatory system in humans with induced lipid malabsorption conditions. Journal of Lipid Research 57:12, pages 2208-2216.
Crossref
Crossref
Morgan A Wyatt, Yasodha Ahilan, Panos Argyropoulos, Christopher N Boddy, Nathan A Magarvey & Paul HM Harrison. (2013) Biosynthesis of ebelactone A: isotopic tracer, advanced precursor and genetic studies reveal a thioesterase-independent cyclization to give a polyketide β-lactone. The Journal of Antibiotics 66:7, pages 421-430.
Crossref
Crossref
Piers Blackett, Jeanie Tryggestad, Sowmya Krishnan, Shibo Li, Weihong Xu, Petar Alaupovic, Carmen Quiroga & Kenneth Copeland. (2013) Lipoprotein abnormalities in compound heterozygous lipoprotein lipase deficiency after treatment with a low-fat diet and orlistat. Journal of Clinical Lipidology 7:2, pages 132-139.
Crossref
Crossref
Štěpán Svačina. 2013. Diabetes. Diabetes
459
464
.
Kristine J. Steffen & Ronette L. Kolotkin. (2012) A Review of the Combination of Phentermine and Topiramate Extended-Release for Weight Loss. Combination Products in Therapy 2:1.
Crossref
Crossref
E L Thomas, A Makwana, R Newbould, A W Rao, G Gambarota, G Frost, B Delafont, R G Mishra, P M Matthews, E S Berk, S M Schwartz, J D Bell & J D Beaver. (2011) Pragmatic study of orlistat 60 mg on abdominal obesity. European Journal of Clinical Nutrition 65:11, pages 1256-1262.
Crossref
Crossref
Steven R. Smith, Kaj S. Stenlof, Frank L. Greenway, John McHutchison, Susan M. Schwartz, Vidhu B. Dev, Evan S. Berk & Roxanne Kapikian. (2012) Orlistat 60 mg Reduces Visceral Adipose Tissue: A 24‐Week Randomized, Placebo‐Controlled, Multicenter Trial. Obesity 19:9, pages 1796-1803.
Crossref
Crossref
Anita Elaine Weidmann, Scott Cunningham, Gwen Gray, Denise Hansford, James McLay, John Broom & Derek Stewart. (2011) Over-the-counter orlistat: early experiences, views and attitudes of community pharmacists in Great Britain. International Journal of Clinical Pharmacy 33:4, pages 627-633.
Crossref
Crossref
Kristine J. Steffen, James E. Mitchell, Daniel le Grange, Scott J. Crow, Evelyn Attia, Cynthia M. Bulik, Jocilyn E. Dellava, Ovidio Bermudez, Ann L. Erickson, Ross D. Crosby & Vidhu P. Bansal‐Dev. (2010) A prevalence study and Description of alli® use by patients with eating disorders. International Journal of Eating Disorders 43:5, pages 472-479.
Crossref
Crossref
Cristina Cruz-Hernandez, Manuel Oliveira, Grégory Pescia, Julie Moulin, Isabelle Masserey-Elmelegy, Fabiola Dionisi & Frédéric Destaillats. (2010) Lipase inhibitor orlistat decreases incorporation of eicosapentaenoic and docosahexaenoic acids in rat tissues. Nutrition Research 30:2, pages 134-140.
Crossref
Crossref
. (2008) Current World Literature. Current Opinion in Endocrinology, Diabetes & Obesity 15:5, pages 470-479.
Crossref
Crossref
Nitesh Sood, William L Baker & Craig I Coleman. (2008) Effect of glucomannan on plasma lipid and glucose concentrations, body weight, and blood pressure: systematic review and meta-analysis. The American Journal of Clinical Nutrition 88:4, pages 1167-1175.
Crossref
Crossref
C. Holzapfel & H. Hauner. (2008) Ernährungstherapeutische Konzepte bei AdipositasNutrition treatment of obesity. Der Gastroenterologe 3:5, pages 383-390.
Crossref
Crossref